血必净注射液预防放射性肺损伤的临床研究

Clinical Research on Xuebijing Injection in Prevention of Radiation-induced Lung Injury

摘要:

目的: 探讨血必净注射液预防非小细胞肺癌(NSCLC)放疗所致放射性肺损伤的疗效。 方法: 将本院放疗科收治的经病理检测证实且需进行放疗的NSCLC患者83例随机分为两组。治疗组42例于放疗第1天起静滴血必净注射液;对照组41例给予单纯放疗。比较两组血清肿瘤坏死因子-α(TNF-α)水平、凝血功能、KPS评分以及随访6个月期间放射性肺损伤的发生率。 结果: 两组患者放疗2周及放疗结束时TNF-α水平显著升高,而治疗组升高幅度显著低于对照组;两组凝血功能均有不同程度的恶化,但治疗组恶化程度显著低于对照组;治疗组放疗2周及放疗结束时KPS评分较放疗前略有下降,而放疗结束后6个月显著升高,且放疗结束时及结束后6个月均显著高于对照组;治疗组早期及晚期放射性肺损伤的发生率均显著低于对照组。 结论: 血必净注射液具有拮抗内毒素、减少炎症因子释放、良性调节抗凝及凝血功能及提高KPS评分作用,可有效预防放射性肺损伤,改善患者生活质量。

Abstract:

Objective:To explore the prevention effect of Xuebijing injection on radiation-induced lung injury in patients with non-small cell lung cancer (NSCLC). Method: Eighty three cases of NSCLC patients underwent radiotherapy and confirmed by pathological examinations were randomly divided into two groups. The treatment group (n=42) received Xuebijing injection from the first day of radiotherapy, the control group (n=41) received radiotherapy alone. The levels of tumor necrosis factor-α (TNF-α), coagulation function, KPS scoring, and incidence of radiation-induced lung injury within 6-month-follow up were observed. Result: The levels of TNF-α in the two groups at the second week and the end of radiotherapy increased obviously, while the increasing degree in the treatment group was obviously smaller than that in the control group. The coagulation function in the two groups had different degree of deterioration, while the deterioration degree in the treatment group was smaller than that in the control group. The KPS scoring in the treatment group at the second week and the end of radiotherapy decreased slightly, and obviously increased 6 months after radiotherapy, and was also higher than that in the control group at the end of radiotherapy and 6 months after the end of radiotherapy. The incidences of early and advanced radiation-induced lung injury in the treatment group were obviously lower than that in the control group. Conclusion: Xuebijing injection has the effect on anti-endotoxin, reducing inflammation factors releasing, adjusting anticoagulation and coagulation function, and increasing the KPS scoring, so as to effectively prevent radiation-induced lung injury and improve the life quality of the patients.